Allergan Second-Quarter Profit Surges on Botox, Namenda

Allergan Plc, which agreed to sell its generics unit to Teva Pharmaceutical Industries Ltd. last month, said second-quarter profit surged 29 percent, fueled by sales of the cosmetic drug Botox and Namenda for Alzheimer’s disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.